| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Delivered ~20% U.S. procedure volume growth in the third quarter |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA |
| 08 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025 |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The statements in this presentation regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, are “forward-looking” statements. These forward-loo... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
A total of 37,674,856 shares of the Company’s common stock were present or represented by proxy at the Annual Meeting, which represented approximately 89% of the Company’s 42,529,059 shares of common stock that were outstanding and entit... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
Achieved ~25% worldwide revenue growth and positive adjusted EBITDA |
| 24 Feb 2025 |
8-K: Results of Operations and Financial Condition
Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26% |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 |
| 05 Aug 2024 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Increases 2024 revenue guidance to $165 million - $167 million |
| 19 Jul 2024 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made as of July 18, 2024, by and between BIXBY SPE FINANCE 11, LLC, a Delaware limited liability company (“Landlord”), and SI-BONE INC., a Delaware corporation (“Tenant”). |
| 26 Jun 2024 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SI-BONE, INC. |
| 06 May 2024 |
8-K: Results of Operations and Financial Condition
SANTA CLARA, Calif. May 6, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024. |
| 26 Feb 2024 |
8-K: Results of Operations and Financial Condition
SANTA CLARA, Calif. February 26, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full yea... |
| 08 Jan 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
This presentation contains “ forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often co... |
Loading...